



2nd July 2013

**Aurobindo Pharma receives USFDA approval for
Rizatriptan Benzoate Orally Disintegrating Tablets**

Aurobindo Pharma Limited is pleased to announce that the company has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Rizatriptan Benzoate Orally Disintegrating Tablets (ODT) 5mg and 10mg (ANDA 203062). The product is ready for launch.

Rizatriptan Benzoate ODT 5mg and 10mg are the generic equivalent of Merck & Co. Inc's Maxalt®-MLT ODT 5mg and 10mg respectively and indicated for the acute treatment of migraine in adults and in pediatric patients 6 to 17 years of age. The annual sale of the product is approximately US\$ 271 million for 12 months ending April 2013 as per IMS.

The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad, India

Aurobindo now has a total of 192 ANDA approvals (164 Final approvals including 4 from Aurolife Pharma LLC and 28 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com